Kala Pharmaceuticals (NASDAQ:KALA) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a report issued on Friday, February 16th.
Other research analysts have also recently issued research reports about the company. Wedbush reiterated a “buy” rating and issued a $46.00 price objective on shares of Kala Pharmaceuticals in a research report on Thursday, November 30th. JPMorgan Chase & Co. set a $35.00 target price on Kala Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, November 19th. Finally, Wells Fargo & Co reissued a “buy” rating on shares of Kala Pharmaceuticals in a report on Friday, January 5th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $35.80.
Kala Pharmaceuticals (NASDAQ KALA) traded up $0.22 during trading on Friday, hitting $16.85. The stock had a trading volume of 210,321 shares, compared to its average volume of 401,759. Kala Pharmaceuticals has a twelve month low of $11.81 and a twelve month high of $26.75. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.00 and a quick ratio of 11.00.
In other news, major shareholder Orbimed Advisors Llc acquired 362,240 shares of the business’s stock in a transaction dated Thursday, February 1st. The shares were bought at an average cost of $15.00 per share, for a total transaction of $5,433,600.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have purchased 1,108,150 shares of company stock worth $15,772,394 over the last quarter.
Several large investors have recently made changes to their positions in KALA. Victory Capital Management Inc. purchased a new stake in shares of Kala Pharmaceuticals during the 3rd quarter valued at about $12,414,000. Bank of New York Mellon Corp acquired a new stake in Kala Pharmaceuticals during the 3rd quarter valued at approximately $540,000. Commonwealth Equity Services Inc acquired a new stake in Kala Pharmaceuticals during the 3rd quarter valued at approximately $360,000. EAM Investors LLC acquired a new stake in Kala Pharmaceuticals during the 3rd quarter valued at approximately $1,353,000. Finally, American International Group Inc. acquired a new position in shares of Kala Pharmaceuticals in the 3rd quarter worth approximately $122,000. Institutional investors and hedge funds own 72.45% of the company’s stock.
Kala Pharmaceuticals Company Profile
Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.